Epigenetics in acute myeloid leukemia

Unravel complex epigenetic mechanisms implicated in acute myeloid leukemia (AML) with our interactive pathway poster, highlighting key targets in this field and our broad range of proteomic tools against these targets, from recombinant antibodies and proteins to ELISA kits and cell lines. 

Download the Epigenetics targets in AML poster.

​Published February 08, 2022

Acute myeloid leukemia (AML) is the most common type of leukemia in adults, characterized by uncontrolled proliferation of abnormal myeloid progenitor cells. Epigenetics alterations, such as DNA methylation or histone modifications, are likely to play a critical role in the initiation and progression of AML. Several studies have found that 70% of recurring mutations in patients with AML occur in gene expression regulators, such as epigenetic proteins, transcription factors, and splicing machinery components^1-4. Furthermore, several epigenetics therapies, including DNA hypomethylating agents, have been approved by regulatory authorities worldwide or are now undergoing early-phase clinical trials⁵.

To help you study epigenetic mechanisms in AML, the poster covers all key established and promising epigenetics targets in acute myeloid leukemia, including:

• Histone modifications, such as H2AR3, H3K4, H3K36, H3K27, H3K9, H3R8, H3K79, H4R3
• Histone methylation/demethylation enzymes, including EZH2, KMT2A, SETD2, G9A (EHMT2), PRMT1, PRMT5, and DOT1L
• DNA methylation enzymes, such as DNMT3A, TET1/2/3, IDH1, IDH2
• Transcription factors, such as HOXA9, PU1, CEBPA, and RUNX1
• RNA binding proteins, including RBM39, IGF2BP1, Musashi 2, hnRNP K, NCL, WT1
• RNA methyltransferase METTL3
• Epigenetic reader BRD4

Once you’ve downloaded the poster, click on the highlighted epigenetic targets to access the range of corresponding products.

References:

1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med, 374 (23), 2209–2221 (2016).
2. Ley TJ, Miller C, Ding L, et al. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368 (22), 2059–2074 (2013).
3. Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366 (12), 1079–1089 (2012).
4. Tyner JW ,  Tognon CE , Bottomly  D , et al. Functional genomic landscape of acute myeloid leukaemia. Nature, 562 (7728), 526–531 (2018).
5. Fennell KA, Bell CC, Dawson MA. Epigenetic therapies in acute myeloid leukemia: where to from here? Blood, 134 (22), 1891–1901 (2019).